EyePoint Pharmaceuticals Inc (EYPT) Stock Price Highs and Lows Over the Last Year

In the latest session, EyePoint Pharmaceuticals Inc (NASDAQ: EYPT) closed at $26.55 up 1.70% from its previous closing price of $26.10. In other words, the price has increased by $+0.44 from its previous closing price. On the day, 691356 shares were traded.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


Sponsored

Ratios:

For a deeper understanding of EyePoint Pharmaceuticals Inc’s stock, let’s take a closer look at its various ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 9.53 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 140.77. For the most recent quarter (mrq), Quick Ratio is recorded 2.28 and its Current Ratio is at 2.35. In the meantime, Its Debt-to-Equity ratio is 0.11 whereas as Long-Term Debt/Eq ratio is at 0.09.

Upgrades & Downgrades

In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, JP Morgan on January 22, 2024, initiated with a Overweight rating and assigned the stock a target price of $35.

On November 02, 2023, Mizuho started tracking the stock assigning a Buy rating and target price of $20.

On April 21, 2023, Robert W. Baird started tracking the stock assigning a Outperform rating and target price of $33.Robert W. Baird initiated its Outperform rating on April 21, 2023, with a $33 target price.

Insider Transactions:

Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Feb 02 when Jones David Scott sold 209 shares for $28.49 per share. The transaction valued at 5,954 led to the insider holds 37,962 shares of the business.

Paggiarino Dario A. sold 49,325 shares of EYPT for $1,265,539 on Jan 26. The Chief Medical Officer now owns 36,505 shares after completing the transaction at $25.66 per share. On Jan 26, another insider, Jones David Scott, who serves as the SVP & Chief Commercial Officer of the company, sold 26,017 shares for $25.38 each. As a result, the insider received 660,370 and left with 37,962 shares of the company.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, EYPT now has a Market Capitalization of 1.30B and an Enterprise Value of 1.17B. For the stock, the TTM Price-to-Sale (P/S) ratio is 30.49 while its Price-to-Book (P/B) ratio in mrq is 15.99. Its current Enterprise Value per Revenue stands at 27.44 whereas that against EBITDA is -11.97.

Stock Price History:

Over the past 52 weeks, EYPT has reached a high of $30.99, while it has fallen to a 52-week low of $2.21. The 50-Day Moving Average of the stock is 24.27, while the 200-Day Moving Average is calculated to be 12.87.

Shares Statistics:

For the past three months, EYPT has traded an average of 1.68M shares per day and 866.38k over the past ten days. A total of 48.84M shares are outstanding, with a floating share count of 44.45M. Insiders hold about 9.00% of the company’s shares, while institutions hold 100.00% stake in the company. Shares short for EYPT as of Jan 31, 2024 were 5.14M with a Short Ratio of 3.06, compared to 5.33M on Dec 29, 2023. Therefore, it implies a Short% of Shares Outstanding of 10.52% and a Short% of Float of 14.44%.

Earnings Estimates

There are 11 different market analysts currently analyzing its stock. On average, analysts expect EPS of -$0.49 for the current quarter, with a high estimate of -$0.29 and a low estimate of -$0.76, while EPS last year was -$1.16. The consensus estimate for the next quarter is -$0.44, with high estimates of -$0.33 and low estimates of -$0.56.

Analysts are recommending an EPS of between -$1.44 and -$2.27 for the fiscal current year, implying an average EPS of -$1.94. EPS for the following year is -$1.75, with 11 analysts recommending between -$0.13 and -$2.5.

Revenue Estimates

A total of 11 analysts believe the company’s revenue will be $8.9M this quarter.It ranges from a high estimate of $14.4M to a low estimate of $200k. As of the current estimate, EyePoint Pharmaceuticals Inc’s year-ago sales were $10.53M, an estimated decrease of -15.50% from the year-ago figure.

A total of 11 analysts have provided revenue estimates for EYPT’s current fiscal year. The highest revenue estimate was $46.4M, while the lowest revenue estimate was $30M, resulting in an average revenue estimate of $40.7M. In the same quarter a year ago, actual revenue was $41.4M, down -1.70% from the average estimate.

Most Popular